Research Information Only — Educational content, not medical advice. GH-axis peptides require physician supervision.
PeptideReport.ai
Compare › Tesamorelin vs CJC-1295

Head-to-Head · GH Axis Hub

Tesamorelin vs CJC-1295

Two GHRH analogs that both raise your own growth hormone — but they're built for different jobs. One is FDA-approved specifically to reduce deep abdominal fat. The other is a general GH-axis anchor, usually paired with ipamorelin. Same family, different assignment.

Both GHRH AnalogsVisceral-Fat vs General GHApproved vs Compounded

The Short Answer

A targeted drug vs a general anchor

Tesamorelin is a GHRH analog with FDA-approved evidence for reducing visceral (deep abdominal) fat in a specific population — the most targeted, evidence-backed role in this pair. CJC-1295 is a research/compounded GHRH analog used more broadly for GH-axis support and body composition, most often combined with ipamorelin for a stronger, synchronized pulse. If visceral fat is the specific target, tesamorelin has the receipts; for general GH-axis work, CJC-1295 (paired) is the common anchor.

Targeted · Approved

Tesamorelin

  • GHRH analog
  • FDA-approved for visceral fat (specific use)
  • Strongest evidence for deep abdominal fat
  • Raises IGF-1
vs
General · Paired

CJC-1295

  • GHRH analog
  • General GH-axis support
  • Usually paired with ipamorelin
  • Research/compounded peptide

Side by Side

The full comparison

ClassTesamorelin: GHRH analogCJC-1295: GHRH analog
Signature useVisceral (abdominal) fat reductionGeneral GH-axis / body composition
EvidenceFDA-approved for its indicationResearch/compounded; commonly paired
Typical pairingUsed on its own for its targetWith ipamorelin (synchronized pulse)
IGF-1Raises IGF-1Raises IGF-1
DosingFasted, bedtime (GH-axis rule)Fasted, bedtime (GH-axis rule)

Which One Fits

Target decides

Tesamorelin if…

  • Deep abdominal (visceral) fat is the specific target
  • You want the FDA-approved evidence for that use
  • Visceral fat is the manifestation of GH decline

CJC-1295 if…

  • General GH-axis support is the goal
  • You're building a paired (with ipamorelin) protocol
  • Sleep, recovery, body recomposition over time
Both share the GH-axis rulesFasted, bedtime dosing (food blunts the pulse), and both raise IGF-1 — cautioned with a cancer history. See the GH Axis hub and Ipamorelin vs Sermorelin for how the pairings fit together.

Common Questions

Tesamorelin vs CJC-1295, answered

What's the difference?
Both are GHRH analogs, but tesamorelin is FDA-approved specifically for visceral fat reduction, while CJC-1295 is a research/compounded GHRH analog used more broadly and usually paired with ipamorelin.
Which is better for belly fat?
Tesamorelin — it has the specific, approved evidence for reducing deep abdominal (visceral) fat. CJC-1295 supports the GH axis generally rather than being a dedicated visceral-fat agent.
Is CJC-1295 always paired with ipamorelin?
Not always, but usually — the GHRH analog plus a ghrelin-mimetic produce a stronger, synchronized GH pulse together than either alone.
Do both need fasted dosing?
Yes — GH-axis peptides are dosed fasted at bedtime because food blunts the pulse, and both raise IGF-1, which is cautioned with a cancer history.

About the Author

SD
Dr. Scott DelBoccio, DMD
Founding Author · PeptideReport.ai

Dr. DelBoccio is a clinician with thirty years of practice and a focus on the GH axis and metabolic medicine. PeptideReport.ai is the clinician-authored, education-only reference the peptide space lacked. No products are sold on this site.

Full Disclaimer

Tesamorelin is FDA-approved for a specific visceral-fat indication; CJC-1295 is a research/compounded peptide. This page is for educational purposes only and does not constitute medical advice. Any use must be under a licensed physician's supervision, with attention to GH-axis cautions including IGF-1 elevation and a cancer history. PeptideReport.ai does not manufacture, sell, or endorse any preparation. Content addresses adults 21 and older. Evidence and regulatory status continue to evolve.